Pertussis Completed Phase 2 Trials for Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)

Also known as: Whooping cough due to Bordetella pertussis / Whooping Cough / Whooping cough due to bordetella pertussis (B. pertussis)

IndicationStatusPhase
DBCOND0014696 (Pertussis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03589768Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their InfantsPrevention
NCT01171989Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DosePrevention
NCT00970307Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of AgePrevention
NCT02301702Maternal Tdap Immunization in GuatemalaPrevention
NCT00355121Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®Prevention
NCT01457495Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered ConcomitantlyPrevention
NCT00362427Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®Prevention
NCT00376779Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of AgePrevention